Alpha Modus Holdings, Inc.
AMOD rates a SELL because the stock still trades around $1.17 despite de minimis reported revenue, deeply negative earnings, a 346.69x P/S, and a 0.09 current ratio, leaving little fundamental support for equity value.
AMOD is a hard stock to own on fundamentals because the current quote still asks investors to capitalize possibility rather than business performance. FY2025 revenue was reported at $0.0B, EPS was -11.60, and operating margin was -73,468.6%. That is not a rough patch in a scaling software model. It is a reminder that the commercial engine has not been demonstrated. Yet the shares still screen at 346.69x P/S against a peer average of 3.5x, which is an extraordinary premium for a company that has not proven monetization.
The bull case rests almost entirely on optionality: a 13-patent portfolio, a tight float, and the idea that one licensing deal or retail deployment could change the narrative fast. That is possible. It is also why the stock can remain volatile even after a 97.7% collapse from the $52.00 52-week high. But optionality is not the same as investment-grade evidence. Without disclosed revenue scale, recurring customers, or improving unit economics, the market is being asked to pay for legal IP claims before seeing durable cash returns from them.
The case depends on three things. First, AMOD must show real commercialization at the next few reports, not just patent announcements. Second, it must stabilize liquidity, because a 0.09 current ratio leaves almost no room for operating misses. Third, management has to rebuild credibility after a volatile earnings record that included a -100.0% EPS miss in May 2026, even though August posted a beat. With no recent earnings-call detail available, there is not enough management commentary to underwrite a sharp inflection.
The stock being down 90.9% versus its 200-day average of $12.86 and 99.8% below its 5-year high does not, by itself, create value. Plenty of broken microcaps get cheaper. At $1.17, the right question is not whether the stock can bounce, it is whether the business has earned the right to a durable valuation floor. The available numbers say no. That keeps the rating at SELL despite the possibility of violent upside in a low-float headline move.
A licensing deal or retail deployment validates the IP, and the tight float amplifies the re-rating despite weak trailing fundamentals.
Patent news supports some floor, but absent revenue scale or balance-sheet improvement the stock drifts around the quant engine's fair value.
Liquidity pressure and another quarter without credible revenue commercialization push the market to value AMOD mostly on residual optionality.
No analyst coverage available to cross-check.
We don't buy stocks where they are, we buy them where they're going.
Forward earnings power is still too speculative to underwrite because trailing results show $0.0B revenue and -11.60 EPS, so even a forward P/E framework is unusable today. The moat is currently more legal than economic, centered on 13 patents, but over the next 3-5 years that moat only matters if retailers or partners adopt the technology at scale before larger software and ad-tech vendors replicate adjacent functionality. AI is more likely a disruption risk than an advantage at this stage, because larger platforms can fold computer vision, retail media workflow, and analytics into broader suites faster than AMOD has shown it can monetize standalone IP. Higher rates, with the 10-year Treasury at 5.29%, also matter here because a pre-profit microcap with weak liquidity gets little benefit of the doubt when capital is expensive.
- 346.69x P/S versus a 3.5x peer average despite FY2025 revenue of $0.0B
- 0.09 current ratio and Financial Health score of 38/100, pointing to financing risk if losses persist
- Price target $1.14, only -2.9% from the current $1.17, supports limited upside even after a -72.01% 3-month drawdown
- The company has built an IP narrative, with a 13th patent announced on 2026-09-03, which could help support licensing discussions if commercial adoption materializes.
- Insiders own 88.2%, which aligns management economically with the equity and can tighten the float in any positive news cycle.
- Market Sentiment score is 87/100, and short interest is only 3.77% of shares with 0.3 days-to-cover, which means the stock is not broadly crowded on the short side.
- The latest reported quarter did show an EPS beat, with 2026-08-14 EPS of -1.02 versus -1.6, a 36.3% positive surprise from a very low base.
- The core issue is missing scale: FY2025 revenue was reported at $0.0B, making the current equity valuation difficult to justify on any conventional software metric.
- Profitability is not just weak but structurally absent, with EPS of -11.60 and an operating margin of -73,468.6% in FY2025.
- Liquidity looks stressed, with a 0.09 current ratio and a Financial risk sub-score of 15.5/25, leaving the company exposed to dilution or other external funding needs.
- Execution credibility is mixed at best: AMOD missed badly on 2026-05-14, reporting -3.2 EPS versus -1.6, a -100.0% miss, before the later beat.
| Metric | Value | Context |
|---|---|---|
| Price target | $1.14 | High confidence, -2.9% versus current $1.17, basis: sales_quality_blend |
| Quant baseline call | HOLD | High conviction from the engine, but fundamentals remain too weak to justify a neutral stance |
| FY2025 Revenue | $0.0B | No meaningful reported scale, core issue in the thesis |
| FY2025 EPS | -11.60 | 205.9% YoY, still deeply loss-making |
| Operating margin | -73468.6% | Extreme negative profitability, prior FY N/A |
| P/S | 346.69x | Versus 3.5x peer average, disconnect with current revenue base |
| Current ratio | 0.09 | Signals weak near-term liquidity |
| Quality / Risk scores | 51/100 and 50/100 | Quality middling, risk moderate overall |
| Ownership | Insiders 88.2%, top-3 institutions 34.5% | Concentrated holder base, very limited float dynamics |
| Short interest | 3.77% | 35,626 shares, 0.3 days-to-cover, down 9.9% |
| 52-week position | $1.12 to $52.00 | Current price is -97.7% below the high |
| Next catalyst | December 2, 2026 earnings | Report due in 62 days |
The biggest risk to the bearish view is that AMOD converts its patent portfolio into meaningful licensing or enterprise revenue from a near-zero base, because with only a 5M float and 88.2% insider ownership, even a small commercial win could move the stock sharply.
The next catalyst is the December 2, 2026 earnings report, where investors need evidence that revenue is becoming real and recurring rather than remaining effectively zero.
Ownership is unusual: insiders own 88.2% and the top three institutions hold 34.5%, which suggests a constrained float and the potential for sharp moves on light volume. But short interest is only 3.77%, or 35,626 shares, down 9.9%, with just 0.3 days-to-cover, so there is no meaningful short squeeze setup to lean on. This is a thin, sentiment-driven stock, not one with broad institutional sponsorship built on fundamentals.
Available disclosure does not show meaningful segment diversification, which itself is a risk because the investment case rests on future commercialization rather than current operating mix.
AMOD's only visible moat today is its patent portfolio, now at 13 patents, tied to retail media handoff and related workflow claims. That can create nuisance value or niche licensing leverage, but it is not yet a proven commercial moat because the company has not demonstrated material revenue, installed-base lock-in, or scale advantages. Durability looks low unless the patents turn into signed customers, royalty streams, or platform adoption.
Capital allocation is hard to call disciplined when the business has not yet shown durable cash generation. Reported FCF, capex, buybacks, and dividends are all $0.0B, which means investors are not being paid to wait and there is no evidence yet of internally funded growth. The practical capital-allocation question is not buybacks or M&A, it is whether management can fund operations without heavily diluting shareholders.
AMOD rates a SELL with High conviction. The stock may remain volatile because insider ownership is high and the float is small, but volatility is not value. The business still lacks the basic proof points needed to support even a $1.17 share price with confidence: real revenue, workable margins, and adequate liquidity. A move to neutral would require evidence of signed commercial adoption and a balance-sheet improvement, not just more patent headlines.
≣ Full research note tap to expand
Executive Summary
SELL, High conviction. AMOD looks like a story stock without operating proof. FY2025 showed $0.0B revenue, EPS of -11.60, and an extreme -73,468.6% operating margin, while the balance sheet screens weak with a 0.09 current ratio. The stock has already collapsed 97.7% from its 52-week high, but that price damage alone is not a reason to buy when valuation still implies a business model that has not yet shown durable commercial traction.
Investment Thesis
AMOD is a hard stock to own on fundamentals because the current quote still asks investors to capitalize possibility rather than business performance. FY2025 revenue was reported at $0.0B, EPS was -11.60, and operating margin was -73,468.6%. That is not a rough patch in a scaling software model. It is a reminder that the commercial engine has not been demonstrated. Yet the shares still screen at 346.69x P/S against a peer average of 3.5x, which is an extraordinary premium for a company that has not proven monetization.
The bull case rests almost entirely on optionality: a 13-patent portfolio, a tight float, and the idea that one licensing deal or retail deployment could change the narrative fast. That is possible. It is also why the stock can remain volatile even after a 97.7% collapse from the $52.00 52-week high. But optionality is not the same as investment-grade evidence. Without disclosed revenue scale, recurring customers, or improving unit economics, the market is being asked to pay for legal IP claims before seeing durable cash returns from them.
The case depends on three things. First, AMOD must show real commercialization at the next few reports, not just patent announcements. Second, it must stabilize liquidity, because a 0.09 current ratio leaves almost no room for operating misses. Third, management has to rebuild credibility after a volatile earnings record that included a -100.0% EPS miss in May 2026, even though August posted a beat. With no recent earnings-call detail available, there is not enough management commentary to underwrite a sharp inflection.
The stock being down 90.9% versus its 200-day average of $12.86 and 99.8% below its 5-year high does not, by itself, create value. Plenty of broken microcaps get cheaper. At $1.17, the right question is not whether the stock can bounce, it is whether the business has earned the right to a durable valuation floor. The available numbers say no. That keeps the rating at SELL despite the possibility of violent upside in a low-float headline move.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Price target | $1.14 | High confidence, -2.9% versus current $1.17, basis: sales_quality_blend |
| Quant baseline call | HOLD | High conviction from the engine, but fundamentals remain too weak to justify a neutral stance |
| FY2025 Revenue | $0.0B | No meaningful reported scale, core issue in the thesis |
| FY2025 EPS | -11.60 | 205.9% YoY, still deeply loss-making |
| Operating margin | -73468.6% | Extreme negative profitability, prior FY N/A |
| P/S | 346.69x | Versus 3.5x peer average, disconnect with current revenue base |
| Current ratio | 0.09 | Signals weak near-term liquidity |
| Quality / Risk scores | 51/100 and 50/100 | Quality middling, risk moderate overall |
| Ownership | Insiders 88.2%, top-3 institutions 34.5% | Concentrated holder base, very limited float dynamics |
| Short interest | 3.77% | 35,626 shares, 0.3 days-to-cover, down 9.9% |
| 52-week position | $1.12 to $52.00 | Current price is -97.7% below the high |
| Next catalyst | December 2, 2026 earnings | Report due in 62 days |
Financial Strength
The balance sheet read is weak. A 0.09 current ratio is the headline number because it implies almost no short-term cushion, and there is no offsetting evidence here of strong cash generation or healthy margins. Reported FCF is $0.0B, profitability is deeply negative, and debt metrics are not usefully disclosed, which leaves investors without a clean bridge to self-funded operations. In a 5.29% 10-year rate environment, that matters more, not less, because unprofitable microcaps face a higher cost of capital and a lower tolerance for funding gaps.
Competitive Position
AMOD's only visible moat today is its patent portfolio, now at 13 patents, tied to retail media handoff and related workflow claims. That can create nuisance value or niche licensing leverage, but it is not yet a proven commercial moat because the company has not demonstrated material revenue, installed-base lock-in, or scale advantages. Durability looks low unless the patents turn into signed customers, royalty streams, or platform adoption.
Management & Guidance
There is no recent earnings-call analysis available, so visibility into management's operating targets is poor. That alone lowers confidence because the company needs to explain how patents become revenue, and the public data here does not show a clear path. The earnings record is mixed rather than trustworthy: AMOD posted a sharp miss on 2026-05-14, then a beat on 2026-08-14. One beat from a low base is not enough to grant management strong credibility without accompanying revenue scale, cash flow progress, or explicit commercialization milestones.
Segment Analysis
- Total company (FY2025 revenue reported at $0.0B): Available disclosure does not show meaningful segment diversification, which itself is a risk because the investment case rests on future commercialization rather than current operating mix.
Capital Allocation
Capital allocation is hard to call disciplined when the business has not yet shown durable cash generation. Reported FCF, capex, buybacks, and dividends are all $0.0B, which means investors are not being paid to wait and there is no evidence yet of internally funded growth. The practical capital-allocation question is not buybacks or M&A, it is whether management can fund operations without heavily diluting shareholders.
Positioning & Flows
Ownership is unusual: insiders own 88.2% and the top three institutions hold 34.5%, which suggests a constrained float and the potential for sharp moves on light volume. But short interest is only 3.77%, or 35,626 shares, down 9.9%, with just 0.3 days-to-cover, so there is no meaningful short squeeze setup to lean on. This is a thin, sentiment-driven stock, not one with broad institutional sponsorship built on fundamentals.
Bull Case
- The company has built an IP narrative, with a 13th patent announced on 2026-09-03, which could help support licensing discussions if commercial adoption materializes.
- Insiders own 88.2%, which aligns management economically with the equity and can tighten the float in any positive news cycle.
- Market Sentiment score is 87/100, and short interest is only 3.77% of shares with 0.3 days-to-cover, which means the stock is not broadly crowded on the short side.
- The latest reported quarter did show an EPS beat, with 2026-08-14 EPS of -1.02 versus -1.6, a 36.3% positive surprise from a very low base.
Bear Case
- The core issue is missing scale: FY2025 revenue was reported at $0.0B, making the current equity valuation difficult to justify on any conventional software metric.
- Profitability is not just weak but structurally absent, with EPS of -11.60 and an operating margin of -73,468.6% in FY2025.
- Liquidity looks stressed, with a 0.09 current ratio and a Financial risk sub-score of 15.5/25, leaving the company exposed to dilution or other external funding needs.
- Execution credibility is mixed at best: AMOD missed badly on 2026-05-14, reporting -3.2 EPS versus -1.6, a -100.0% miss, before the later beat.
Valuation & Price Target
Engine price target $1.14 (-2.9% vs current), High confidence.
- P/S Multiple: $0 (1% weight)
- Quality-adjusted: $1.18 (20% weight)
The quant baseline is HOLD with a $1.14 target, only -2.9% below the current $1.17. The downgrade to SELL is deliberate because the downside case is not about near-term target math alone, it is about business quality: $0.0B revenue, -11.60 EPS, -73,468.6% operating margin, and a 0.09 current ratio are too weak to treat as a stable hold, especially with a still-extreme 346.69x P/S. The quality-adjusted method at $1.18 effectively says the stock is fairly priced, but fair value on a company without visible operating proof offers no margin of safety. There is no analyst coverage to cross-check, which leaves the fundamentals carrying even more weight.
Risk Assessment
Risk score 50/100 (Moderate). The biggest risk to the bearish view is that AMOD converts its patent portfolio into meaningful licensing or enterprise revenue from a near-zero base, because with only a 5M float and 88.2% insider ownership, even a small commercial win could move the stock sharply.
The Bottom Line
AMOD rates a SELL with High conviction. The stock may remain volatile because insider ownership is high and the float is small, but volatility is not value. The business still lacks the basic proof points needed to support even a $1.17 share price with confidence: real revenue, workable margins, and adequate liquidity. A move to neutral would require evidence of signed commercial adoption and a balance-sheet improvement, not just more patent headlines.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr